“Performance measurement is an essential tool for the health care system to improve itself and give patients better care at a lower cost. I look forward to being on the forefront of quality innovation and helping our clients in the transition to value-based care.”
David Blaisdell, a Director at Discern Health, leads and manages client projects, providing insight and subject matter expertise, particularly on quality landscapes and measure gap identification. David has led and contributed to projects focused on oncology quality measurement, most recently working with the National Pharmaceutical Council, as well as the Society for Immunotherapy of Cancer, to identify key gaps in measures used in accountability programs and opportunities for measure development. Through this experience, David can help clients navigate the oncology measure and value-based policy environment and define strategies for success.
In his time at Discern, David has led the review of the quality measurement and policy landscape for several therapeutic and topic areas and developed strategies for clients on opportunities to succeed within the value-based marketplace. David has led and contributed to projects convening multiple stakeholders, including providers, professional societies, patient groups, industry coalitions, and life sciences companies, to analyze gaps in measurement and define priorities for new measure development.
Before joining Discern, David was a legislative aide at the Massachusetts House of Representatives, coordinating constituent services and supporting policy analysis. Prior to this role, David served as Research Director for Voters Count, a voter advocacy nonprofit.
Areas of Expertise
- Measure gap identification and concept proposal strategies
- The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), including the Merit-based Incentive Payment System and Alternative Payment Models
- Accountable Care Organizations
- BA, Writing, Literature, and Publishing – Emerson College
- Baltimore, MD